U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C21H21FN4O3.ClH
Molecular Weight 432.876
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Pradofloxacin hydrochloride

SMILES

Cl.[H][C@]12CN(C[C@@]1([H])NCCC2)C3=C(C#N)C4=C(C=C3F)C(=O)C(=CN4C5CC5)C(O)=O

InChI

InChIKey=WUPBAVNMWVWXBI-VFZPIINCSA-N
InChI=1S/C21H21FN4O3.ClH/c22-16-6-13-18(26(12-3-4-12)9-15(20(13)27)21(28)29)14(7-23)19(16)25-8-11-2-1-5-24-17(11)10-25;/h6,9,11-12,17,24H,1-5,8,10H2,(H,28,29);1H/t11-,17+;/m0./s1

HIDE SMILES / InChI

Molecular Formula C21H21FN4O3
Molecular Weight 396.4148
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Pradofloxacin (trade name Veraflox) is a 3rd generation enhanced spectrum veterinary antibiotic of the fluoroquinolone class. It was developed by Bayer HealthCare AG, Animal Health GmbH, and received approval from the European Commission in April 2011 for prescription-only use in veterinary medicine for the treatment of bacterial infections in dogs and cats. The primary mode of action of fluoroquinolones involves interaction with enzymes essential for major DNA functions such as replication, transcription, and recombination. The primary targets for Pradofloxacin are the bacterial DNA gyrase and topoisomerase IV enzymes. Reversible association between Pradofloxacin and DNA gyrase or DNA topoisomerase IV in the target bacteria results in inhibition of these enzymes and rapid death of the bacterial cell. The rapidity and extent of bacterial killing are directly proportional to the drug concentration.

Originator

Curator's Comment: # Bayer Aktiengesellschaft

Approval Year

PubMed

PubMed

TitleDatePubMed
Studies on a new device for drug delivery to the eye.
2005 Feb
In vivo tolerance and kinetics of a novel ocular drug delivery device.
2006 Nov 28
Pradofloxacin in the treatment of canine deep pyoderma: a multicentred, blinded, randomized parallel trial.
2007 Jun
Mutant prevention concentration of pradofloxacin against Porphyromonas gingivalis.
2007 Mar 31
Pharmacokinetics of pradofloxacin and doxycycline in serum, saliva, and tear fluid of cats after oral administration.
2008 Apr
Evaluation of pradofloxacin for the treatment of feline rhinitis.
2008 Oct
Use of pradofloxacin to treat experimentally induced Mycoplasma hemofelis infection in cats.
2009 Jan
Identification of Qnr and AAC(6')-1b-cr plasmid-mediated fluoroquinolone resistance determinants in multidrug-resistant Enterobacter spp. isolated from extraintestinal infections in companion animals.
2010 Jul 14
Molecular mechanisms of Bartonella henselae resistance to azithromycin, pradofloxacin and enrofloxacin.
2010 Mar
Haemotropic mycoplasmas: what's their real significance in cats?
2010 May
Fluoroquinolone resistance mechanisms in multidrug-resistant Escherichia coli isolated from extraintestinal infections in dogs.
2010 Nov 20
Evaluation of the clinical efficacy of pradofloxacin tablets for the treatment of canine pyoderma.
2010 Sep-Oct
Patents

Sample Use Guides

Administer 3.0 mg/kg bodyweight of pradofloxacin once daily.
Route of Administration: Oral
The MIC of pradofloxacinc was determined by broth microdilution according to Clinical and Laboratory Standards Institute (CLSI) standards,6 within the concentration range 0.008–16 μg/mL. The MICs of enrofloxacin and ciprofloxacin were determined using commercial stripsd on Mueller–Hinton 2 agar inoculated with a bacterial suspension (density of 0.5 McFarland) and incubated for 24 h at 35°C. The reference strain S. aureus ATCC 25923 was used as a quality control for MIC determination with the commercial strips, according to the manufacturer’s instructions.
Substance Class Chemical
Created
by admin
on Sat Dec 16 19:35:44 UTC 2023
Edited
by admin
on Sat Dec 16 19:35:44 UTC 2023
Record UNII
PX8LA4EH3R
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
Pradofloxacin hydrochloride
Common Name English
3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, hydrochloride (1:1)
Systematic Name English
3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-, monohydrochloride, (4aS-cis)-
Systematic Name English
Code System Code Type Description
CAS
195532-14-0
Created by admin on Sat Dec 16 19:35:44 UTC 2023 , Edited by admin on Sat Dec 16 19:35:44 UTC 2023
PRIMARY
PUBCHEM
9802883
Created by admin on Sat Dec 16 19:35:44 UTC 2023 , Edited by admin on Sat Dec 16 19:35:44 UTC 2023
PRIMARY
FDA UNII
PX8LA4EH3R
Created by admin on Sat Dec 16 19:35:44 UTC 2023 , Edited by admin on Sat Dec 16 19:35:44 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY